New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
05:58 EDTBAXSBaxano Surgical pullback brings attractive risk/reward, says Brean Capital
Brean Capital believes the recent pullback in shares of Baxano Surgical provides a compelling risk/reward profile relative to its $4 price target. Brean thinks that if Baxano can prove itself over the next two years, it is likely to be taken out. The firm reiterates a Buy rating on the name.
News For BAXS From The Last 14 Days
Check below for free stories on BAXS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 18, 2014
07:34 EDTBAXSBaxano Surgical says economic analysis of the AxiaLIF accepted for publication
Baxano Surgical announced that the Journal of Managed Care Medicine, a peer-reviewed national publication, has accepted an economic analysis of the AxiaLIF pre-sacral interbody fusion procedure in comparison to transforaminal lumbar interbody fusion, or TLIF. The analysis, conducted by Scott Parker, MD, Director of the Spinal Column Surgical Quality and Outcomes Research Laboratory at Vanderbilt University, and Dr. Matt McGirt, Carolina Neurosurgery and Spine Associates, Adjunct Associate Professor, University of North Carolina, analyzed the bibliography for AxiaLIF and TLIF procedures and assessed relative costs by looking at reoperation rates, complication rates, blood loss and OR time. The study found that AxiaLIF resulted in an approximately $4,500 lower cost per procedure when looking at these procedural parameters.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use